BioXcel Therapeutics raises $7.8M in registered direct offering and amends prior warrants

BioXcel Therapeutics, Inc.

Sold 2,480,294 common shares and pre-funded warrants for 2,020,491 shares at combined $1.739/unit, plus accompanying warrants.
Gross proceeds ~$7.8M; placement agent fees 6% cash plus 180,031 warrants at $2.0175.
Warrant amendment reduces exercise price to $1.614 on 1,385,083 prior warrants and extends term to 5 years; investor paid ~$173k.
Proceeds used for working capital and general corporate purposes.
Offering closed March 11, 2026; common stock trades on Nasdaq under BTAI.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioXcel Therapeutics, Inc. entered into Purchase Agreement with the Purchaser valued at approximately $7.8 million (effective 2026-03-10).

Action: entry
Agreement: equity purchase
Counterparty: the Purchaser
Value: approximately $7.8 million
Effective: 2026-03-10

Exact text from the filing

On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioXcel Therapeutics, Inc. amended Warrant Amendment Agreement with the Purchaser valued at approximately $173,135 (effective 2026-03-10).

Action: amendment
Agreement: equity purchase
Counterparty: the Purchaser
Value: approximately $173,135
Effective: 2026-03-10

Exact text from the filing

In connection with the Offering, pursuant to the terms of a Warrant Amendment Agreement, dated as of March 10, 2026 (the “Warrant Amendment Agreement”), the exercise price of certain outstanding warrants issued on March 27, 2024 and November 25, 2024 to purchase up to an aggregate of 1,385,083 shares of Common Stock held by the Purchaser was reduced to $1.614 per share

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-026409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.